TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/16/2026
Back to search
Official data from USPTO
ALIBREX
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
ALIBREX
ST13
US500000088299485Class
5, 42, 44
Filing
88299485
Registration
6159041
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
29
Latest update
04/17/2026
Trademark type
Word
Nice classes
5, 42, 44
Filing date
02/13/2019
Registration date
09/22/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
09/22/2020
Last transaction
04/17/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
04/16/2019
First use in commerce
04/16/2019
Drawing code
4
Owner type
03
Owner location
CUPERTINO, CA, US
Examiner
JAGANNATHAN, SIDDHARTH
Law office
M50
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
ONECELL DIAGNOSTICS, INC.
Cadex Genomics, Corp.
Representatives
Alison M. Caless Cantor Colburn LLP
Technical classification
Nice Classes
Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Medical diagnostic assays for testing of bodily fluidsassays used to evaluate the effectiveness of cancer drug therapy and to identify patients who are not responding to cancer drug therapy; Medical diagnostic test media in the form of reagents used to evaluate the effectiveness of cancer drug therapy and to identify patients who are not responding to cancer drug therapy; medical diagnostic kits comprised of medical diagnostic reagents and assays used to evaluate the effectiveness of cancer drug therapy and to identify patients who are not responding to cancer drug therapy
Class 42
Medical and scientific research in the field of medical diagnostic assays and clinical testing services for the purpose of testing of bodily fluids used to evaluate the effectiveness of cancer drug therapy and to identify patients who are not responding to cancer drug therapy
Class 44
Medical testing for diagnostic or treatment purposesfor the purpose of testing of bodily fluids used to evaluate the effectiveness of cancer drug therapy and to identify patients who are not responding to cancer drug therapy
Publications
History of USPTO decisions and trademark events.
29 publications found
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/16/2026
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/16/2026
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
04/16/2026
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
04/16/2026
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
09/22/2025
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
04/02/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
09/22/2020
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
08/18/2020
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
08/15/2020
SUPC
STATEMENT OF USE PROCESSING COMPLETE
08/14/2020
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
08/13/2020
IUAF
USE AMENDMENT FILED
08/04/2020
EISU
TEAS STATEMENT OF USE RECEIVED
08/04/2020
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
02/04/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/10/2019
PUBO
PUBLISHED FOR OPPOSITION
12/10/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/20/2019
ALIE
ASSIGNED TO LIE
11/01/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/28/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/26/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/25/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/25/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
04/29/2019
GNRT
NON-FINAL ACTION E-MAILED
04/29/2019
CNRT
NON-FINAL ACTION WRITTEN
04/29/2019
DOCK
ASSIGNED TO EXAMINER
04/23/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/07/2019
NWAP
NEW APPLICATION ENTERED
02/16/2019
Continuous trademark protection
Get notified about every new filing that threatens ALIBREX or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.